dexamethasone + diphenhydramine + ranitidine

This premedication regimen is a specific combination of dexamethasone, diphenhydramine, and an H2 blocker (such as ranitidine) utilized in a Columbia University Phase 2 clinical trial (NCT02013440) for patients with newly diagnosed stage II-III breast cancer. The regimen is administered 30-60 minutes prior to each paclitaxel infusion to prevent hypersensitivity reactions and mitigate side effects associated with taxane-based chemotherapy. Dexamethasone acts as a corticosteroid to reduce inflammation and immune response, diphenhydramine is an H1-antagonist used to prevent allergic reactions, and ranitidine (or an equivalent H2 blocker) provides additional prophylaxis against histamine-mediated reactions. This supportive care regimen was used alongside the investigational drug propranolol and standard neoadjuvant chemotherapy.

Other names

Premedicationpaclitaxel premedication